A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1862-1878

  Kalappa, Bopanna I ^a   Sun, Fen ^b   Johnson, Stephen R ^c   Jin, Kunlin ^b   Uteshev, Victor V ^a,b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c Carbon Dynamics Institute   (United States)

Author keywords

7 nAChR; anoxic depolarization; choline; cortex; hippocampus; ischaemia; neuroprotection; PNU 120596; PNU120596

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYLISOXAZOL 3 YL)UREA; BUNGAROTOXIN RECEPTOR; CHOLINE; METHYLLYCACONITINE; NEUROPROTECTIVE AGENT; PNU 120596; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; GABAERGIC TRANSMISSION; HIPPOCAMPAL CA1 REGION; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL LESION; NERVE CONDUCTION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

Α7 NACHR; ANOXIC DEPOLARIZATION; CHOLINE; CORTEX; HIPPOCAMPUS; ISCHAEMIA; NEUROPROTECTION; PNU-120596; PNU120596;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; BRAIN ISCHEMIA; CHOLINE; HIPPOCAMPUS; ISOXAZOLES; MALE; NEURONS; NEUROPROTECTIVE AGENTS; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84881248457     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12247     Document Type: Article

References (77)

1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. (2007). Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655-1711.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Alkondon M, Albuquerque EX, (2006). Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway. J Pharmacol Exp Ther 318: 268-275.
4. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX, (1997). Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9: 2734-2742.
5. Avignone E, Frenguelli BG, Irving AJ, (2005). Differential responses to NMDA receptor activation in rat hippocampal interneurons and pyramidal cells may underlie enhanced pyramidal cell vulnerability. Eur J Neurosci 22: 3077-3090.
6. Beal CC, (2010). Gender and stroke symptoms: a review of the current literature. J Neurosci Nurs 42: 80-87.
7. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM, (1986). Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17: 1304-1308.
8. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, et al. (2010). In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334: 875-886.
9. Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, et al. (1997). Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol 387: 385-398.
10. Brott T, Bogousslavsky J, (2000). Treatment of acute ischemic stroke. N Engl J Med 343: 710-722.
11. Brown KL, Comalli DM, Biasi MD, Woodruff-Pak DS, (2010). Trace eyeblink conditioning is impaired in alpha7 but not in beta2 nicotinic acetylcholine receptor knockout mice. Front Behav Neurosci 4: 166.
12. Castro NG, Albuquerque EX, (1995). alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys J 68: 516-524.
13. De Rosa MJ, Dionisio L, Agriello E, Bouzat C, Esandi Mdel C, (2009). Alpha 7 nicotinic acetylcholine receptor modulates lymphocyte activation. Life Sci 85: 444-449.
14. Del Barrio L, Martin-de-Saavedra MD, Romero A, Parada E, Egea J, Avila J, et al. (2011). Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2* nicotinic stimulation. Toxicol Sci 123: 193-205.
15. Dijkhuizen RM, Beekwilder JP, van der Worp HB, Berkelbach van der Sprenkel JW, Tulleken KA, Nicolay K, (1999). Correlation between tissue depolarizations and damage in focal ischemic rat brain. Brain Res 840: 194-205.
16. Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, Zheng L, et al. (2011). Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4- pyridinyl)-5-thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 336: 560-574.
17. Djuricic B, Olson SR, Assaf HM, Whittingham TS, Lust WD, Drewes LR, (1991). Formation of free choline in brain tissue during in vitro energy deprivation. J Cereb Blood Flow Metab 11: 308-313.
18. Faghih R, Gopalakrishnan SM, Gronlien JH, Malysz J, Briggs CA, Wetterstrand C, et al. (2009). Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3- propionyl-1H-pyrrol-1-yl)benzenesulfonami de (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. J Med Chem 52: 3377-3384.
19. Ferrer I, Soriano MA, Vidal A, Planas AM, (1995). Survival of parvalbumin-immunoreactive neurons in the gerbil hippocampus following transient forebrain ischemia does not depend on HSP-70 protein induction. Brain Res 692: 41-46.
20. Frahm C, Haupt C, Witte OW, (2004). GABA neurons survive focal ischemic injury. Neuroscience 127: 341-346.
21. Freitas K, Carroll FI, Damaj MI, (2012). The antinociceptive effects of nicotinic receptors alpha7-positive allosteric modulators in murine acute and tonic pain models. J Pharmacol Exp Ther 344: 264-275.
22. Freund TF, Buzsaki G, (1996). Interneurons of the hippocampus. Hippocampus 6: 347-470.
23. Fucile S, (2004). Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35: 1-8.
24. Furlan AJ, (2002). Acute stroke therapy: beyond i.v. tPA. Cleve Clin J Med 69: 730-734.
25. Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, et al. (2007). Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724.
26. Guan ZZ, Zhang X, Ravid R, Nordberg A, (2000). Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74: 237-243.
27. Gusev AG, Uteshev VV, (2010). Physiological concentrations of choline activate native alpha7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3- yl)-urea]. J Pharmacol Exp Ther 332: 588-598.
28. Guseva MV, Hopkins DM, Scheff SW, Pauly JR, (2008). Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury. J Neurochem 25: 975-983.
29. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J, (2008). Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice. Neurochem Int 52: 972-978.
30. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, et al. (2005). A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25: 4396-4405.
31. Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, et al. (2001). Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci U S A 98: 4710-4715.
32. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, (1999). Stroke. Neurologic and functional recovery the Copenhagen Stroke Study. Phys Med Rehabil Clin N Am 10: 887-906.
33. Kalappa BI, Gusev AG, Uteshev VV, (2010). Activation of functional alpha7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596. Plos ONE 5: e13964.
34. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. (2000). Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283: 1151-1158.
35. Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger AJ, (1996). The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 4: 1429-1446.
36. Kelso ML, Pauly JR, (2011). Therapeutic targets for neuroprotection and/or enhancement of functional recovery following traumatic brain injury. Prog Mol Biol Transl Sci 98: 85-131.
37. Kem WR, (2000). The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113: 169-181.
38. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
39. Klein J, Holler T, Cappel E, Koppen A, Loffelholz K, (1993). Release of choline from rat brain under hypoxia: contribution from phospholipase A2 but not from phospholipase D. Brain Res 630: 337-340.
40. Klein J, Koppen A, Loffelholz K, (1998). Regulation of free choline in rat brain: dietary and pharmacological manipulations. Neurochem Int 32: 479-485.
41. Li Y, Papke RL, He YJ, Millard WJ, Meyer EM, (1999). Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. Brain Res 830: 218-225.
42. Lo EH, (2008). A new penumbra: transitioning from injury into repair after stroke. Nat Med 14: 497-500.
43. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
44. McLean SL, Idris NF, Grayson B, Gendle DF, Mackie C, Lesage AS, et al. (2011). PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol 26: 1265-1270.
45. Meyer EM, Tay ET, Zoltewicz JA, Papke RL, Meyers C, King M, et al. (1998). Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284: 1026-1032.
46. Olincy A, Stevens KE, (2007). Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 74: 1192-1201.
47. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
48. Papke RL, Papke JKP, (2002). Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br J Pharmacol 137: 49-61.
49. Papke RL, Bencherif M, Lippiello P, (1996). An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci Lett 213: 201-204.
50. Papke RL, Meyer E, Nutter T, Uteshev VV, (2000). alpha 7 receptor-selective agonists and modes of alpha 7 receptor activation. Eur J Pharmacol 393: 179-195.
51. Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, et al. (2013). The microglial alpha7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox Signal, in press.
52. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA, (2009). Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78: 677-685.
53. Ren K, Thinschmidt J, Liu J, Ai L, Papke RL, King MA, et al. (2007). alpha7 Nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance, and tau hyperphosphorylation. Neuroscience 145: 314-322.
54. Richard Green A, Odergren T, Ashwood T, (2003). Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 24: 402-408.
55. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. (2012). Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
56. Rosa AO, Egea J, Gandia L, Lopez MG, Garcia AG, (2006). Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the alpha7 nAChR subtype. J Mol Neurosci 30: 61-62.
57. Rossi DJ, Oshima T, Attwell D, (2000). Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 403: 316-321.
58. Sarter M, Parikh V, (2005). Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci 6: 48-56.
59. Scremin OU, Jenden DJ, (1989). Focal ischemia enhances choline output and decreases acetylcholine output from rat cerebral cortex. Stroke 20: 92-95.
60. Sharma G, Vijayaraghavan S, (2001). Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci U S A 98: 4148-4153.
61. Shimohama S, Greenwald DL, Shafron DH, Akaike A, Maeda T, Kaneko S, et al. (1998). Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 779: 359-363.
62. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, et al. (2004). Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89: 337-343.
63. Sitzia F, Brown JT, Randall AD, Dunlop J, (2011). Voltage- and temperature-dependent allosteric modulation of alpha7 nicotinic receptors by PNU-120596. Front Pharmacol 2: 81.
64. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR, (1990). A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10: 290-293.
65. Tanaka E, Yamamoto S, Kudo Y, Mihara S, Higashi H, (1997). Mechanisms underlying the rapid depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. J Neurophysiol 78: 891-902.
66. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD, (2010). Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 16: 323-343.
67. Uteshev VV, (2010). Evaluation of Ca2+ permeability of nicotinic acetylcholine receptors in hypothalamic histaminergic neurons. Acta Biochim Biophys Sin (Shanghai) 42: 8-20.
68. Uteshev VV, (2012a). alpha7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca (2+) optimum. Adv Exp Med Biol 740: 603-638.
69. Uteshev VV, (2012b). Somatic integration of single ion channel responses of alpha7 nicotinic acetylcholine receptors enhanced by PNU-120596. Plos ONE 7: e32951.
70. Uteshev VV, Meyer EM, Papke RL, (2003). Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors. J Neurophysiol 89: 1797-1806.
71. Vernino S, Amador M, Luetje CW, Patrick J, Dani JA, (1992). Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron 8: 127-134.
72. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388.
73. Whiteaker P, Davies AR, Marks MJ, Blagbrough IS, Potter BV, Wolstenholme AJ, et al. (1999). An autoradiographic study of the distribution of binding sites for the novel alpha7-selective nicotinic radioligand [3H]- methyllycaconitine in the mouse brain. Eur J Neurosci 11: 2689-2696.
74. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV, (2011). Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 6: 11.
75. Young GT, Zwart R, Walker AS, Sher E, Millar NS, (2008). Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A 105: 14686-14691.
76. Zhan RZ, Nadler JV, Schwartz-Bloom RD, (2006). Depressed responses to applied and synaptically-released GABA in CA1 pyramidal cells, but not in CA1 interneurons, after transient forebrain ischemia. J Cereb Blood Flow Metab 26: 112-124.
77. Zhan RZ, Nadler JV, Schwartz-Bloom RD, (2007). Impaired firing and sodium channel function in CA1 hippocampal interneurons after transient cerebral ischemia. J Cereb Blood Flow Metab 27: 1444-1452.